Tranexamic acid tablets

There are various natural antagonists of plasmin (pro) in the blood circulation, such as antiplasmin, etc. Under normal circumstances, the antifibrinolytic activity in the blood is many times higher than the fibrinolytic activity, so fibrinolytic bleeding will not occur. However, these antagonists cannot block the activation of activators (such as urokinase) adsorbed on the fibrin network to form plasmin. Plasmin is a peptide endonuclease that can cleave the arginine and lysine peptide chains of fibrinogen in a neutral environment to form fibrin degradation products and cause blood clot dissolution and bleeding. Plasminogen is specifically adsorbed on fibrin through the lysine binding site in its molecular structure. Lysine can competitively inhibit this adsorption, reduce the adsorption rate of plasminogen, and thus reduce the degree of plasminogen activation to reduce bleeding. The chemical structure of this product is similar to lysine (1,5-diaminohexanoic acid), so it can also competitively inhibit the adsorption of plasminogen on fibrin, thereby preventing its activation and protecting fibrin from being degraded and dissolved by plasmin, ultimately achieving a hemostatic effect. This product can also directly inhibit the activity of plasmin and reduce the role of plasmin in activating complement (C1), thereby preventing the occurrence of hereditary angioedema.

The chemical name of this product is: -4-aminomethylcyclohexanecarboxylic acid. Molecular formula: C8H15NO2 Molecular weight: 157.21

This product is white tablets.

This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product should be used with caution before heparinization. This product is also suitable for: ① traumatic or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, thyroid glands, and liver; ② used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase; ③ fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism; ④ menorrhagia, hyphema, and severe epistaxis due to local increased fibrinolysis; ⑤ used to prevent or reduce bleeding after tooth extraction or oral surgery in hemophiliacs with factor VIII or factor IX deficiency; ⑥ central artery

Oral administration: 1-1.5 g at a time, 2-6 g per day. To prevent bleeding before and after surgery, refer to the above dosage. To treat bleeding caused by primary fibrinolysis, the dosage can be increased as appropriate.

This product has fewer side effects than 6-aminocaproic acid. Occasionally, drug overdose may cause intracranial thrombosis and bleeding. Other side effects include diarrhea, nausea and vomiting; less common are menstrual discomfort (caused by blood coagulation during menstruation). Patients who must continue to use this product for a long time should undergo ophthalmological examinations and monitoring (such as vision tests, vision, visual field and fundus).

It is contraindicated for those who are allergic to this product.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

1. It is incompatible with thrombolytic agents such as penicillin or urokinase; 2. The combination of oral contraceptives, estrogen or prothrombin complex concentrates with this product may increase the risk of thrombosis.

Keep away from light and store in a sealed container.

0.125 g

24 months